[1]
Laurell CB, Eriksson S. The electrophoretic a-1-globulin pattern of serum in a-1-antitrypsin deficiency. Scand J Clin Lab Invest 1963; 15(2): 132-40.
[2]
Sveger T. Liver disease in alpha1-antitrypsin deficiency detected by screening of 200,000 infants. N Engl J Med 1976; 294(24): 1316-21.
[3]
Campos MA, Wanner A, Zhang G, Sandhaus RA. Trends in the diagnosis of symptomatic patients with alpha1-antitrypsin deficiency between 1968 and 2003. Chest 2005; 128(3): 1179-86.
[4]
Lara B. COPD and alpha-1-antitrypsin deficiency. Arch Bronconeumol 2010; 46(Suppl. 4): 2-8.
[5]
Rahaghi FF, Sandhaus RA, Strange C, et al. The prevalence of alpha-1 antitrypsin deficiency among patients found to have airflow obstruction. COPD 2012; 9(4): 352-8.
[6]
Sharp HL, Bridges RA, Krivit W, Freier EF. Cirrhosis associated with alpha-1-antitrypsin deficiency: A previously unrecognized inherited disorder. J Lab Clin Med 1969; 73(6): 934-9.
[7]
Sharp HL. History of the first description of childhood liver disease in AATD. COPD 2013; 10(Suppl. 1): 13-6.
[8]
American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2003; 168(7): 818-900.
[9]
McLean C, Greene CM, McElvaney NG. Gene targeted therapeutics for liver disease in alpha-1 antitrypsin deficiency. Biologics 2009; 3: 63-75.
[10]
Fairbanks KD, Tavill AS. Liver disease in alpha 1-antitrypsin deficiency: A review. Am J Gastroenterol 2008; 103(8): 2136-41.
[11]
Stoller JK, Aboussouan LS. A review of alpha1-antitrypsin deficiency. Am J Respir Crit Care Med 2012; 185(3): 246-59.
[12]
Fregonese L, Stolk J, Frants RR, Veldhuisen B. Alpha-1 antitrypsin Null mutations and severity of emphysema. Respir Med 2008; 102(6): 876-84.
[13]
Molloy K, Hersh CP, Morris VB, et al. Clarification of the risk of chronic obstructive pulmonary disease in alpha1-antitrypsin deficiency PiMZ heterozygotes. Am J Respir Crit Care Med 2014; 189(4): 419-27.
[14]
Lomas DA. Twenty years of polymers: A personal perspective on alpha-1 antitrypsin deficiency. COPD 2013; 10(Suppl. 1): 17-25.
[15]
Teckman JH. Liver disease in alpha-1 antitrypsin deficiency: Current understanding and future therapy. COPD 2013; 10(Suppl. 1): 35-43.
[16]
Lomas DA, Evans DL, Finch JT, Carrell RW. The mechanism of Z alpha 1-antitrypsin accumulation in the liver. Nature 1992; 357(6379): 605-7.
[17]
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med 2009; 6(7): e1000097.
[18]
Ebell MH, Siwek J, Weiss BD, et al. Strength Of Recommendation taxonomy (SORT): A patient-centered approach to grading evidence in the medical literature. J Am Board Fam Pract 2004; 17(1): 59-67.
[19]
Moyer V, Freese DK, Whitington PF, et al. Guideline for the evaluation of cholestatic jaundice in infants: Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2004; 39(2): 115-28.
[20]
Francavilla R, Castellaneta SP, Hadzic N, et al. Prognosis of alpha-1-antitrypsin deficiency-related liver disease in the era of paediatric liver transplantation. J Hepatol 2000; 32(6): 986-92.
[21]
Kalsheker NA. alpha1-Antitrypsin deficiency: Best clinical practice. J Clin Pathol 2009; 62(10): 865-9.
[22]
Sveger T, Eriksson S. The liver in adolescents with alpha 1-antitrypsin deficiency. Hepatology 1995; 22(2): 514-7.
[23]
Dawwas MF, Davies SE, Griffiths WJ, Lomas DA, Alexander GJ. Prevalence and risk factors for liver involvement in individuals with PiZZ-related lung disease. Am J Respir Crit Care Med 2013; 187(5): 502-8.
[24]
Clark VC, Dhanasekaran R, Brantly M, Rouhani F, Schreck P, Nelson DR. Liver test results do not identify liver disease in adults with alpha(1)-antitrypsin deficiency. Clin Gastroenterol Hepatol 2012; 10(11): 1278-83.
[25]
Rudnick DA, Perlmutter DH. Alpha-1-antitrypsin deficiency: A new paradigm for hepatocellular carcinoma in genetic liver disease. Hepatology 2005; 42(3): 514-21.
[26]
Rakela J, Goldschmiedt M, Ludwig J. Late manifestation of chronic liver disease in adults with alpha-1-antitrypsin deficiency. Dig Dis Sci 1987; 32(12): 1358-62.
[27]
De Tommaso AM, Rossi CL, Escanhoela CA, et al. Diagnosis of alpha-1-antitrypsin deficiency by DNA analysis of children with liver disease. Arq Gastroenterol 2001; 38(1): 63-8.
[28]
Filipponi F, Soubrane O, Labrousse F, et al. Liver transplantation for end-stage liver disease associated with alpha-1-antitrypsin deficiency in children: Pretransplant natural history, timing and results of transplantation. J Hepatol 1994; 20(1): 72-8.
[29]
Rashid ST, Corbineau S, Hannan N, et al. Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. J Clin Invest 2010; 120(9): 3127-36.
[30]
Kemmer N, Kaiser T, Zacharias V, Neff GW. Alpha-1-antitrypsin deficiency: Outcomes after liver transplantation. Transplant Proc 2008; 40(5): 1492-4.
[31]
Bakula A, Socha P, Pawlowska J, Teisseyre M, Jankowska I, Kalicinski P. Good and bad prognosis of alpha-1-antitrypsin deficiency in children: When to list for liver transplantation. Transplant Proc 2007; 39(10): 3186-8.
[32]
Hughes MG Jr, Khan KM, Gruessner AC, et al. Long-term outcome in 42 pediatric liver transplant patients with alpha 1-antitrypsin deficiency: A single-center experience. Clin Transplant 2011; 25(5): 731-6.
[33]
Prachalias AA, Kalife M, Francavilla R, et al. Liver transplantation for alpha-1-antitrypsin deficiency in children. Transpl Int 2000; 13(3): 207-10.
[34]
Vennarecci G, Gunson BK, Ismail T, et al. Transplantation for end stage liver disease related to alpha 1 antitrypsin. Transplantation 1996; 61(10): 1488-95.
[35]
Jain AB, Patil V, Sheikh B, et al. Effect of liver transplant on pulmonary functions in adult patients with alpha 1 antitrypsin deficiency: 7 cases. Exp Clin Transplant 2010; 8(1): 4-8.
[36]
Koczulla R, Bittkowski N, Andress J, et al. The German registry of individuals with alpha-1-antitrypsin deficiency--a source for research on patient care. Pneumologie 2008; 62(11): 655-8.
[37]
Stoller JK, Brantly M. The challenge of detecting alpha-1 antitrypsin deficiency. COPD 2013; 10(Suppl. 1): 26-34.
[38]
Fromer L. Improving diagnosis and management of alpha-1 antitrypsin deficiency in primary care: Translating knowledge into action. COPD 2010; 7(3): 192-8.
[39]
Taliercio RM, Chatburn RL, Stoller JK. Knowledge of alpha-1 antitrypsin deficiency among internal medicine house officers and respiratory therapists: Results of a survey. Respir Care 2010; 55(3): 322-7.
[40]
Silverman EK, Sandhaus RA. Clinical practice. Alpha1-antitrypsin deficiency. N Engl J Med 2009; 360(26): 2749-57.
[41]
Campos M, Shmuels D, Walsh J. Detection of alpha-1 antitrypsin deficiency in the US. Am J Med 2012; 125(7): 623-4.
[42]
Bals R, Koczulla R, Kotke V, Andress J, Blackert K, Vogelmeier C. Identification of individuals with alpha-1-antitrypsin deficiency by a targeted screening program. Respir Med 2007; 101(8): 1708-14.
[43]
Aboussouan LS, Stoller JK. Detection of alpha-1 antitrypsin deficiency: A review. Respir Med 2009; 103(3): 335-41.
[44]
Hogarth DK, Rachelefsky G. Screening and familial testing of patients for alpha 1-antitrypsin deficiency. Chest 2008; 133(4): 981-8.
[45]
Thelin T, Sveger T, McNeil TF. Primary prevention in a high-risk group: smoking habits in adolescents with homozygous alpha-1-antitrypsin deficiency (ATD). Acta Paediatr 1996; 85(10): 1207-12.
[46]
Coors ME, Moseley R, McGorray S. Informed consent process in Alpha-1 testing of at-risk children: views of parents and adults tested as children. COPD 2011; 8(1): 30-8.
[47]
Klitzman R. The impact of social contexts in testing for alpha-1 antitrypsin deficiency: The roles of physicians and others. Genet Test Mol Biomarkers 2009; 13(2): 269-76.
[48]
Sveger T, Thelin T, McNeil TF. Young adults with alpha 1-antitrypsin deficiency identified neonatally: Their health, knowledge about and adaptation to the high-risk condition. Acta Paediatr 1997; 86(1): 37-40.
[49]
Sveger T, Thelin T, McNeil TF. Neonatal alpha1-antitrypsin screening: Parents’ views and reactions 20 years after the identification of the deficiency state. Acta Paediatr 1999; 88(3): 315-8.
[50]
Sveger T, Thelin T. A future for neonatal alpha1-antitrypsin screening? Acta Paediatr 2000; 89(6): 628-31.
[51]
Carroll TP, O’Connor CA, Floyd O, et al. The prevalence of alpha-1 antitrypsin deficiency in Ireland. Respir Res 2011; 12: 91.
[52]
Corda L, Medicina D, La Piana GE, et al. Population genetic screening for alpha1-antitrypsin deficiency in a high-prevalence area. Respiration 2011; 82(5): 418-25.
[53]
Topic A, Prokic D, Stankovic I. Alpha-1-antitrypsin deficiency in early childhood. Fetal Pediatr Pathol 2011; 30(5): 312-9.
[54]
Wewers MD, Casolaro MA, Crystal RG. Comparison of alpha-1-antitrypsin levels and antineutrophil elastase capacity of blood and lung in a patient with the alpha-1-antitrypsin phenotype null-null before and during alpha-1-antitrypsin augmentation therapy. Am Rev Respir Dis 1987; 135(3): 539-43.
[55]
Seersholm N, Wencker M, Banik N, et al. Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group. Eur Respir J 1997; 10(10): 2260-3.
[56]
Wencker M, Banik N, Buhl R, Seidel R, Konietzko N. Long-term treatment of alpha1-antitrypsin deficiency-related pulmonary emphysema with human alpha1-antitrypsin. Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL)-alpha1-AT-study group. Eur Respir J 1998; 11(2): 428-33.
[57]
Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med 1998; 158(1): 49-59.
[58]
Dirksen A, Dijkman JH, Madsen F, et al. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. Am J Respir Crit Care Med 1999; 160(5 Pt 1): 1468-72.
[59]
Dirksen A, Piitulainen E, Parr DG, et al. Exploring the role of CT densitometry: A randomised study of augmentation therapy in alpha1-antitrypsin deficiency. Eur Respir J 2009; 33(6): 1345-53.
45
9
1
